Moreover, Han et al. [86] demonstrated that erlotinib as neoadjuvant treatment in patients with stage IIIA-N2 NSCLC and with an activating EGFR mutation is feasible. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.